Cannabinoid Encyclopedia

Safety guide

Drug interactions: what to know

A source-linked guide to Drug interactions, the situations researchers have examined, and the details that can change risk.

Updated July 2026 6 research sources Source-linked research review

The short answer

Why does Drug interactions matter?

Drug interactions is an important cannabinoid safety topic. Studies and reviews examine CBD. This page brings together 5 research reviews. The available sources help map the question but do not support a broad conclusion. The compound, dose, route, other medications, and individual health context all matter. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about Drug interactions.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on Drug interactions covers CBD; those areas should not be combined into one claim. 1

  2. 2

    The available sources help map the question but do not support a broad conclusion. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about Drug interactions

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

CBD

Research involving CBD contributes to the larger Drug interactions question. Risk can change with dose, route, formulation, other substances, medications, and the person being studied. 2

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

Not prominent

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

5 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

Not prominent

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 1 of 6 research source could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on Drug interactions is not one kind of study. This source set includes 5 narrative or expert reviews. 3

The recorded populations or models include people or patients (5 sources) and pediatric, adolescent, or developmental context (1 source). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is drug-interaction or safety-relevant outcomes (6 sources). Closely related outcome names can still describe different measurements. 5

The Drug interactions source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.

On this page, this source examines CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes. 1

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
drug-interaction or safety-relevant outcomes
Evidence stage
evidence still limited

narrative or expert review

Cannabidiol's impact on drug-metabolization.

On this page, this source examines CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes. 2

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
drug-interaction or safety-relevant outcomes
Evidence stage
evidence still limited

narrative or expert review

Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm.

On this page, this source examines CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes. 3

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
drug-interaction or safety-relevant outcomes
Evidence stage
evidence still limited

narrative or expert review

Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.

On this page, this source examines CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes. 4

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
drug-interaction or safety-relevant outcomes
Evidence stage
evidence still limited

narrative or expert review

Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use.

On this page, this source examines CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes. 5

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
drug-interaction or safety-relevant outcomes
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

This page is already focused on Drug interactions. Risk can change with the cannabinoid, amount, route, frequency, formulation, other substances, medications, age, pregnancy, and underlying health conditions. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What is the main research question about Drug interactions?

The literature on this page centers on CBD. The available sources help map the question but do not support a broad conclusion. 1

How should I read the sources?

Start with the study design, then check the product, dose, route, population, outcome, and safety information. 2

Does this page give medical advice?

No. It explains published research and links to sources; it does not provide a diagnosis, treatment plan, or personal dosing advice. 3

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. narrative or expert review; evidence still limited PubMed 32918835 DOI 10.1111/epi.16674
  2. 2
    Cannabidiol's impact on drug-metabolization. narrative or expert review; evidence still limited PubMed 37541924 DOI 10.1016/j.ejim.2023.07.029
  3. 3
    Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. narrative or expert review; evidence still limited PubMed 39854828 DOI 10.1016/j.yebeh.2024.110261
  4. 4
    Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. narrative or expert review; evidence still limited PubMed 39007525 DOI 10.1002/epi4.12956
  5. 5
    Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. narrative or expert review; evidence still limited PubMed 31288397 DOI 10.3390/jcm8070989
  6. 6
    A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. evidence still limited PubMed 35156171 DOI 10.1007/s40263-022-00898-1
See all 6 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Cannabidiol's impact on drug-metabolization. narrative or expert review; evidence still limited / 1 linked research note PubMed 37541924
  2. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. evidence still limited / 1 linked research note PubMed 35156171
  3. Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. narrative or expert review; evidence still limited / 1 linked research note PubMed 39007525
  4. Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. narrative or expert review; evidence still limited / 1 linked research note PubMed 39854828
  5. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. narrative or expert review; evidence still limited / 1 linked research note PubMed 31288397
  6. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. narrative or expert review; evidence still limited / 1 linked research note PubMed 32918835